BiotechTube

SHR8058 eye drops + saline eye drops.

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Treatment of Dry Eye Disease With Meibomian Gland Dysfunction

Conditions

Treatment of Dry Eye Disease With Meibomian Gland Dysfunction

Trial Timeline

Feb 4, 2021 → Sep 7, 2021

NCT ID
NCT05515471

About SHR8058 eye drops + saline eye drops.

SHR8058 eye drops + saline eye drops. is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Treatment of Dry Eye Disease With Meibomian Gland Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT05515471. Target conditions include Treatment of Dry Eye Disease With Meibomian Gland Dysfunction.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05515471Phase 3Completed

Competing Products

20 competing products in Treatment of Dry Eye Disease With Meibomian Gland Dysfunction

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
77
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
77
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
77
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
77
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
77
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
77
Irinotecan liposome、5-Fluorouracil、Leucovorin + Placebo、5-Fluorouracil、LeucovorinJiangsu Hengrui MedicinePhase 3
77
Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + PrednisoneJiangsu Hengrui MedicinePhase 2
52
Risankizumab + ComparatorAbbViePre-clinical
23
Chemotherapy + Cross-over to OsimertinibAstraZenecaPhase 3
77
AZD6765 + Placebo to AZD6765AstraZenecaPhase 2
52
TC-5214 + PlaceboAstraZenecaPhase 1
33
ACS patients treated with OAPAstraZenecaPre-clinical
23
AZD6738AstraZenecaPhase 1
33
MK-1942 + PlaceboMerckPhase 2
52
5-FU + Folinic Acid + Irinotecan + Cetuximab + AvelumabMerckPhase 2
52
simvastatin/ezetimibe + atorvastatin 20mgMerckApproved
85
BKM120NovartisPhase 2
52
LEE011NovartisPhase 2
52
AFQ056 + PlaceboNovartisPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85